Full Breakdown
Oral GLP-1 Obesity Pills Set for Indian Market in 2027
By Drooid · · How we work
Core Event: Anticipated 2027 Launch of Oral Wegovy and Foundayo
Novo Nordisk’s oral semaglutide (oral Wegovy) and Eli Lilly’s oral GLP-1 agonist orforglipron (Foundayo) are slated for India in the first half of 2027. Both have been filed with Indian regulators and will target patients who avoid weekly injections.
Background & Context
India’s obesity-drug market has been dominated by injectable GLP-1s such as Lilly’s tirzepatide (Mounjaro) and Novo’s injectable Wegovy. About 15-20 % of eligible patients refuse injections, according to diabetologist Rajiv Kovil. Generic semaglutide entered India in 2026, widening price competition. In the United States, oral GLP-1s now account for roughly one-third of obesity prescriptions, with Novo holding about two-thirds of that share.
Key Figures & Groups
- David Ricks — Chair and CEO, Eli Lilly
- Mike Doustdar — CEO, Novo Nordisk
- Rajiv Kovil — Diabetologist, Mumbai
- Vyankatesh Shivane — Senior Endocrinologist, Jaslok Hospital, Mumbai
- Martin Holst Lange — Chief Scientific Officer, Novo Nordisk
Data & Statistics
- Oral GLP-1s achieve 12-15 % average weight loss; injectables 15-22 %.
- A 100 kg patient on oral Wegovy would weigh ~85-88 kg; on an injectable ~78-85 kg.
- Generic semaglutide in India sells for INR1,500-INR5,500 per month; Lilly’s Mounjaro costs INR13,000-INR25,000 per month.
- The U.S. FDA approved orforglipron for long-term weight management on April 1 2026.
Official Statements & Responses
Lilly’s $1 billion India investment is on track, embedding teams with local labs to produce active ingredients and finished dosages at scale. A senior unnamed Novo official emphasized awareness of India’s price sensitivity, though pricing details remain undisclosed.
Kovil noted that oral pills will attract “needle-phobic” patients and may allow general physicians to prescribe GLP-1 therapy more readily. Shivane added that oral GLP-1s could help patients maintain weight loss achieved with injectables.
Conflicting Reports & Gaps
Sources differ on which company will launch first: insiders suggest Lilly’s Foundayo could arrive in January-February 2027, while other reports place Novo’s oral Wegovy later in the first half. No firm launch price has been announced.
Verbatim Quotes
- “We’re ready to go as soon as the Indian authorities say yes,” — David Ricks, Eli Lilly CEO
- “There are at least 15-20% of patients who do not take the injectable because of the fear,” — Rajiv Kovil
What’s Next
Regulatory clearance from India’s drug authority remains the decisive step before any launch. Both firms have indicated readiness for a 2027 rollout, and Lilly’s investment will continue to fund contract-manufacturing partnerships and a Hyderabad technology centre of over 600 engineers. Market observers will watch pricing announcements and the pace of generic competition as the oral GLP-1 segment matures.